H.C. Wainwright downgraded Lumos Pharma (LUMO) to Neutral from Buy with a price target of $4.25, down from $28, after the company entered into a definitive merger agreement whereby Double Point Ventures will acquire 100% of Lumos’ outstanding shares of common stock at a price of $4.25 per share in cash.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter